Current Report Filing (8-k)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
Date of Report (Date of earliest event reported): May 12, 2021
REGEN BIOPHARMA, INC.
(Exact name of small business issuer as specified in its
or other jurisdiction of incorporation or organization)
Employer Identification No.)
Commission File No. 333-191725
711 S. Carson Street, Suite 4, Carson City, Nevada,
(Address of Principal Executive Offices)
(619) 722 5505
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act (17
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
Item 8.01 Other Events.
On May 12, 2021 Regen Biopharma, Inc. (the “Company”) executed a
consulting agreement with Biotech Research Group Corporation (the
“Consultant”), an FDA Specialist Group and Global Regulatory and
Scientific Experts, for the purpose of review and guidance with
regard to the planned reinstatement of the Company’s inactive
Investigational New Drug applications (INDs) #15376 and #16200
filed with the United States Food and Drug Administration (“FDA”).
The securing of the services to be provided to the Company pursuant
to this consulting agreement marks the first step taken by the
Company with regard to activating the Company’s currently inactive
applications to initiate clinical trials.
In December 2015 Company was granted permission by the FDA allowing
for initiation of clinical trials of the Company’s HemaXellerate
therapy under its IND #15376. HemaXellerate is a personalized
immune-modulatory cell therapy that has demonstrated benefit in
animal models of aplastic anemia.
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
May 13, 2021